[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452304":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":45,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Odense University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"transgender women",null,"transgender women eligeble to start gender affirming hormone treatment",[13],"Other: standard treatment",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"standard treatment","starndard treatment for transgender women",[9],[20],{"name":21,"affiliation":5,"role":22},"Dorte Glintborg","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+4565411807","dorte.glintborg@rsyd.dk",[29],{"facility":30,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"OdenseUH","RECRUITING","Odense","5230","Denmark","DK",{"type":37,"coordinates":38},"Point",[39,40],10.38831,55.39594,{"lat":40,"lon":39},[43],{"name":44,"role":22,"phone":10,"phoneExt":10,"email":10},"Marianne Andersen, DMSci",{"type":22,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Marianne Andersen","Clinical professor","100452304",false,"NCT05169762","Feminizing Treatment in Transgender Women and Non-binary Persons","Feminizing Treatment in Transgender Women and Non-binary Persons BODY IDENTITY CLINIC - ESTROGEN","BIC-Estrogen","Inclusion Criteria:\n\n* assigned male at birth and eligeble for gender affirming feminizing treatment\n\nExclusion Criteria:\n\nnone\n\n\\-","MALE","18 Years",{"count":58,"type":59},100,"ESTIMATED","OBSERVATIONAL","Cohort study in 100 transgender women treated with gender affirming hormone treatment. Follow up affter 1year, 3 years, 5 years and 10 years, Outcomes regarding cardiovascular effects of hormone treatment.",[63],"Transgenderism",[65,66,67],"gender affirming hormone treatment","estrogen","cardiovascular risk","2025-03-18",{"date":70,"type":71},"2025-03-21","ACTUAL",{"date":73,"type":71},"2022-02-01",{"date":75,"type":59},"2035-09-01",{"name":5,"class":6},1]